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Letters to the EditorFavorable association between genetic polymorphisms near the
IL28B gene and hepatic steatosis: Direct or indirect?To the Editor,
We read with great interest the article by Tillmann et al. [1] that
investigated the association between IL28B polymorphisms and
hepatic steatosis, both of which are associated with a response
to combination therapy with peginterferon (PEG-IFN) and ribavi-
rin. It will provide new insight into the role of IL28B polymor-
phisms on the resistance to combination therapy against
hepatitis C virus (HCV) infection.
Previous studies have reported the inﬂuence of amino acid
substitutions at residue 70 of the HCV core region (from arginine
to glutamine or histidine) on the resistance to combination ther-
apy with PEG-IFN and ribavirin in patients infected with HCV
genotype 1b [2–4]. In addition, prior studies have identiﬁed an
association between amino acid substitutions at HCV core 70
and hepatic steatosis [5,6]. The percentage of patients with the
mutant amino acid at residue 70 of the HCV core region increases
with the progression of chronic hepatitis, suggesting that the
mutation of the amino acid at residue 70 occurs during the nat-
ural course of chronic HCV infection [7]. Several recent studies
have reported a lower prevalence of mutant amino acids at
HCV core 70 in patients who have the IL28B polymorphism that
is associated with a favorable response to combination therapy
with PEG-IFN and ribavirin (i.e., CC genotype of rs12979860
and TT genotype of rs8099917) than in patients who have an
unfavorable genotype [8,9]. These reports suggest that the muta-
tion frequency of the HCV core 70 amino acid may differ accord-
ing to the genetic polymorphism near the IL28B gene.
We analyzed polymorphisms of rs8099917 that corresponded
to those of rs12979860, the rate of which is more than 99% of indi-
viduals of Japanese ethnicity [10], amino acid substitutions at HCV
core 70, and hepatic steatosis based on biopsy specimens, which
were obtained just prior to the start of the therapy and evaluated
with the same criteria used by Tillmann et al., in our 122 Japanese
Mongolian patients infected with HCV genotype 1b. We found
higher likelihoods of sustained virologic response in patients with
the TT genotype of rs8099917, in patients with arginine at residue
70of theHCVcore region, and in patientswithout steatosis.Wedid
not ﬁnd signiﬁcant association between IL28B polymorphisms and
hepatic steatosis (absence of steatosis: TT genotype, 66 out of 85
(77.6%) vs. TG/GG genotype, 22 out of 37 (59.5%), p = 0.0658). We
found signiﬁcant associations between IL28B polymorphisms and
the amino acid at residue 70 of the HCV core region (patients with
arginine at HCV core 70: TT genotype, 71 out of 85 (83.5%) vs. TG/
GGgenotype, 14 out of 37 (37.8%), p <0.0001) and also between the
amino acid at HCV core 70 and hepatic steatosis (absence of stea-
tosis: arginine at HCV core 70, 73 of 85 (85.9%) vs. glutamine/histi-
dine at HCV core 70, 15 of 37 (40.5%), p <0.0001). These
associations may indicate that the polymorphisms near the IL28B
gene may inﬂuence the mutation of the amino acid at residue 70
of the HCV core region, and that the amino acid mutation at HCVJournal of Hepatologycore 70 may inﬂuence hepatic steatosis over the course of chronic
HCV infection.
There are differences between our Japanese Mongolian popu-
lation and the population studied by Tillmann et al. including eth-
nicity, the rate of correspondence between rs12979860 and
rs8099917, the frequency of the mutation at residue 70 of the
HCV core region, and the rate of hepatic steatosis. Furthermore,
the number of patients infected with HCV genotype 1b in the Till-
mann et al. cohort is unknown. Despite these facts, it would be
interesting if they were to investigate the association of amino
acid substitutions at residue 70 of the HCV core both with
IL28B polymorphisms and with hepatic steatosis.
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To the Editor:
We thank Drs. Toyoda and Kumada for raising the additional point
that HCV amino acid substitutions have also been demonstrated
to inﬂuence steatosis in the setting of HCV infection. In their study
of 122 patients, 85 of whom had a beneﬁcial IL28B genotype, Toy-
oda and Kumada found a trend for steatosis to be associated with
IL28B polymorphism, as only 22% of the patients with beneﬁcial
genotype have steatosis compared to 40% of patients with the less
beneﬁcial genotype. Thus, their r, though not signiﬁcant, is in line
with our study, where we likewise found a 25% and 27% higher
rate of steatosis in patients with the less beneﬁcial IL28B (‘‘non-
C/C’’ for rs12979860 or ‘‘non-T/T’’ for rs8999017) genotype in
two different cohorts of 145 and 180 patients, respectively. Simi-
lar to our and Toyoda and Kumada’s results, Cai et al. found an
association between the beneﬁcial IL28B genotype and lower ste-
atosis frequency [1]. However, a three center study by Trépo et al.
failed to ﬁnd a relevant association between IL28B genotype and
steatosis, according to their statement [2]. This latter paper, how-
ever, did not show the data, and therefore it cannot be assessed
whether the association was absent or only not signiﬁcant. Toy-
oda and Kumada’s study showed a similar trend for steatosis with
IL28B, whereby IL28B is associated with different mutations in the
core region, the HCV core mutation clearly shows a higher associ-
ation with steatosis.
In our article, we indicate that response to treatment in rela-
tion to steatosis seems unlikely to be explained by IL28B alone,
and though not speciﬁcally mentioned, IL28B is likely not solely
responsible for the association with steatosis. We had a small
cohort of 54 non-genotype 1 patients of whom 19 were genotype
3 and 35 were genotype 2. Despite the fact that steatosis tended
to be higher in ‘‘non-C/C’’ patients (4/20 [20%] vs. 7/15 [46%] in
genotype 2 patients and 4/8 [50%] vs. 7/11 [63%] in genotype 3
patients; Table 1) this was not signiﬁcant. However, the trend
was similar across genotypes. Furthermore, we have data on
genotype 1a and 1b in 60 and 75 patients from the ﬁbrosis study,
respectively. In concordance with the overall results, steatosis
was less frequently present in C/C genotype patients with both
HCV genotype 1a and 1b (Table 1).
A possible explanation lies in the virus itself as the authors
correctly point out with a focus on HCV’s core protein. Unfortu-
nately, we do not have the core antigen sequence of our patients.
A previous work by Jhaveri et al. suggested a role for amino acids
182 and 186 of the core protein, linking steatosis in vitro to stea-
tosis [3], but certainly amino acid 70 seems to be especially rele-
vant in genotype 1b infection. There is also some evidence
indicating that not all differences can be explained by viral core
sequence variation [4].
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e 1. Frequency of steatosis.
Presence of steatosis
Non-CC 19/43 (44.2%)
CC 2/17 (11.8%) p = 0.019
Non-CC 28/56 (50%)
CC 4/19 (21%) p = 0.034
Non-CC 7/15 (46%)
CC 4/20 (20%) n.s.
Non-CC 7/11 (63%)
CC 4/8 (50%) n.s.
not signiﬁcant.
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